These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 36897735)

  • 1. Efficacy and safety of PD1/PDL1 inhibitors combined with radiotherapy and anti-angiogenic therapy for solid tumors: A systematic review and meta-analysis.
    Xian F; Wu J; Zhong L; Xu G
    Medicine (Baltimore); 2023 Mar; 102(10):e33204. PubMed ID: 36897735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of PD1/PDL1 inhibitors combined with radiotherapy and antiangiogenic drugs for hepatocellular carcinoma: a systematic review and meta-analysis.
    Xian F; Wu J; Yuan YL; Bie J; Xu GH
    Eur Rev Med Pharmacol Sci; 2023 Feb; 27(4):1494-1502. PubMed ID: 36876689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant Therapy With PD1/PDL1 Inhibitors for Human Cancers: A Systematic Review and Meta-Analysis.
    Jin Y; Wei J; Weng Y; Feng J; Xu Z; Wang P; Cui X; Chen X; Wang J; Peng M
    Front Oncol; 2022; 12():732814. PubMed ID: 35280727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Anti-PD1/PDL1 in Advanced Biliary Tract Cancer: A Systematic Review and Meta-Analysis.
    Jiang Q; Huang J; Zhang B; Li X; Chen X; Cui B; Li S; Guo G
    Front Immunol; 2022; 13():801909. PubMed ID: 35309350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The benefit and risk of PD-1/PD-L1 inhibitors plus anti-angiogenic agents as second or later-line treatment for patients with advanced non-small-cell lung cancer: a systematic review and single-arm meta-analysis of prospective clinical trials.
    Chen S; Mo W; Jiang W; Zhou S; Gan H; Yu Q
    Front Immunol; 2023; 14():1218258. PubMed ID: 37614237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-angiogenic therapy for high-grade glioma.
    Ameratunga M; Pavlakis N; Wheeler H; Grant R; Simes J; Khasraw M
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008218. PubMed ID: 30480778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD‑1/PD‑L1 immune checkpoint inhibitors in neoadjuvant therapy for solid tumors (Review).
    Tang Q; Zhao S; Zhou N; He J; Zu L; Liu T; Song Z; Chen J; Peng L; Xu S
    Int J Oncol; 2023 Apr; 62(4):. PubMed ID: 36866750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness of immune checkpoint inhibitors and other treatment modalities in patients with advanced mucosal melanomas: a systematic review and individual patient data meta-analysis.
    Teo AYT; Yau CE; Low CE; Pereira JV; Ng JYX; Soong TK; Lo JYT; Yang VS
    EClinicalMedicine; 2024 Nov; 77():102870. PubMed ID: 39416390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proton beam radiotherapy combined with anti-PD1/PDL1 immune checkpoint inhibitors for advanced hepatocellular carcinoma.
    Su CW; Hou MM; Huang PW; Chou YC; Huang BS; Tseng JH; Hsu CW; Chang TC; Lin SM; Lin CC
    Am J Cancer Res; 2022; 12(4):1606-1620. PubMed ID: 35530291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of adjuvant therapy with PD‑1/PD‑L1 inhibitors in cancer.
    Mo DC; Liang ZY; Chen L; Huang JF; Luo PH; Wang HL
    Exp Ther Med; 2022 Dec; 24(6):749. PubMed ID: 36561965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of lenvatinib combined with PD‑1/PD‑L1 inhibitors in the treatment of hepatocellular carcinoma: A meta‑analysis and systematic review.
    Zhang B; Su L; Lin Y
    Oncol Lett; 2024 Jul; 28(1):312. PubMed ID: 38803443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The benefits and risks of CTLA4 inhibitor plus PD1/PDL1 inhibitor in stage IIIB/IV non-small cell lung cancer: A systematic analysis and meta-analysis based on randomized controlled trials.
    Liu Q; Fang Z; Liu M; Xu R; Yi F; Wei Y; Zeng L; Zhang W
    J Clin Pharm Ther; 2021 Dec; 46(6):1519-1530. PubMed ID: 34101874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of PD1/PDL1 blockades versus docetaxel in patients with pretreated advanced non-small-cell lung cancer: a meta-analysis.
    Liu J; Zhong Y; Peng S; Zhou X; Gan X
    Onco Targets Ther; 2018; 11():8623-8632. PubMed ID: 30584321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
    Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X
    Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.
    Nishijima TF; Shachar SS; Nyrop KA; Muss HB
    Oncologist; 2017 Apr; 22(4):470-479. PubMed ID: 28275115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse events of immunotherapy in non-small cell lung cancer: A systematic review and network meta-analysis.
    Zhou C; Li M; Wang Z; An D; Li B
    Int Immunopharmacol; 2022 Jan; 102():108353. PubMed ID: 34883352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of anti-angiogenic drug monotherapy and combination therapy for ovarian cancer: a meta-analysis and trial sequential analysis of randomized controlled trials.
    Xie Y; Zhou F
    Front Pharmacol; 2024; 15():1423891. PubMed ID: 38860165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of PD-1/PD-L1 inhibitors in triple-negative breast cancer: a systematic review and meta-analysis.
    Zhang M; Song J; Yang H; Jin F; Zheng A
    Acta Oncol; 2022 Sep; 61(9):1105-1115. PubMed ID: 35939538
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Research Trends and Most Influential Clinical Studies on Anti-PD1/PDL1 Immunotherapy for Cancers: A Bibliometric Analysis.
    Liu Y; Xu Y; Cheng X; Lin Y; Jiang S; Yu H; Zhang Z; Lu L; Zhang X
    Front Immunol; 2022; 13():862084. PubMed ID: 35493449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.